Sonoma Pharmaceuticals (SNOA) Earnings Date & Reports

Key Takeaways

• Sonoma Pharmaceuticals reported record quarterly revenue of $6.4 million, up 60% year over year and above the roughly $4.99 million consensus estimate.
• Net loss narrowed sharply to $0.3 million, or $0.09 per share, compared with a $1.2 million loss, or $0.76 per share, in the prior-year quarter.
• The company achieved its first-ever positive adjusted EBITDA (earnings before interest, taxes, depreciation, and amortization), a key profitability milestone.
• Gross margin expanded to 40% from 36% a year earlier, while operating expenses remained essentially flat.
• U.S. revenue surged 141% year over year, driven by over-the-counter product sales and new distributor growth.
• For more detail on the company's Major News, Today's Price Move, Price Targets, and Forecast, visit the dedicated ticker pages.
• Explore Trending AI Robots to see AI-driven trading strategies currently gaining traction in the market.

Earnings Context and Why It Matters

Sonoma Pharmaceuticals develops and manufactures stabilized hypochlorous acid (HOCl) products used in wound care, eye care, dermatology, podiatry, animal health, and non-toxic disinfection. For a small-cap company that has historically posted consistent losses, the fiscal first quarter of 2027 represented a meaningful inflection point. Investors have long watched whether Sonoma's commercial strategy could translate revenue growth into a path toward profitability. The combination of record sales, expanding gross margins, flat operating expenses, and the company's first positive adjusted EBITDA signals that operating leverage is beginning to materialize. Because the company remains unprofitable on a GAAP (Generally Accepted Accounting Principles) basis and operates with a limited cash balance, this quarterly report carries outsized weight for shareholders evaluating the durability of the turnaround.

Reported Results

For its first fiscal quarter ended June 30, 2026, Sonoma Pharmaceuticals reported total revenue of $6.4 million, a 60% increase from $4.0 million in the same period last year and above the consensus estimate of approximately $4.99 million. U.S. revenue rose 141%, or $1.4 million, while Europe grew 34%.

Gross profit came in at $2.6 million, representing a 40% gross margin compared with 36% a year earlier. Total operating expenses held flat at $2.6 million, demonstrating the operating leverage in the business model. Loss from operations narrowed to just $40,000 from $1.1 million in the prior-year quarter.

The company's net loss for the quarter was $0.3 million, or $0.09 per share (basic and diluted), down 88% from a net loss per share of $0.76 a year ago. Sonoma also recorded an EBITDA gain of about $0.1 million, its first positive adjusted EBITDA, compared with an EBITDA loss of $1.0 million in the prior-year period. As of June 30, 2026, the company held $5.3 million in cash and cash equivalents.

AI Screener

Tickeron's AI Screener is an AI-powered stock and ETF discovery tool designed to help traders and investors filter the market based on technical patterns, fundamentals, trends, volatility, and AI-driven signals. Users can scan thousands of stocks and ETFs using customizable filters such as industry, market capitalization, technical indicators, price patterns, and performance metrics. The screener is built to surface trade ideas, trending stocks, breakout candidates, and market opportunities more efficiently than manual screening. For investors following small-cap names like Sonoma Pharmaceuticals, it can provide a faster way to identify comparable setups and emerging trends across the healthcare sector.

Market Reaction and Investor Sentiment

Sonoma Pharmaceuticals trades as a micro-cap stock with a market capitalization of only a few million dollars, which makes its share price especially sensitive to news and low trading volume. The stock has remained under significant pressure over the past year, trading near the lower end of its 52-week range. The August 6, 2026 report delivered results that beat consensus on both revenue and the bottom line, and the achievement of positive adjusted EBITDA marked a notable shift in the company's narrative. However, investors have continued to weigh the progress against ongoing concerns, including the company's GAAP losses, a still-modest cash balance, and the dilutive effect of a substantially higher share count. Sentiment heading into the next report will likely hinge on whether Sonoma can sustain its revenue momentum and extend its profitability milestone.

Forward Outlook and Key Factors to Monitor

Following this report, investors will be watching whether Sonoma can build on its first-ever positive adjusted EBITDA and maintain the pace of revenue growth. The company's U.S. expansion, driven by over-the-counter products and new distributors, will be a central area of focus, as will the performance of its European business, which has benefited from favorable exchange rates.

Regulatory progress remains an important catalyst. In June 2026, Sonoma received a new 510(k) clearance from the U.S. Food and Drug Administration (FDA) for its Microdacyn Wound Irrigation Solution, including expanded claims and additional packaging configurations. New distribution agreements in Taiwan, Vietnam, and the United States also support the commercial pipeline.

At the same time, several factors deserve attention. The company's share count increased substantially during the quarter, which dilutes per-share metrics and can pressure the stock. Its cash position of $5.3 million, while improved, still requires disciplined cost management as the company continues to pursue growth. Margin sustainability, order timing in Asia and Latin America, and any potential capital-raising activity will all be key variables to monitor in the quarters ahead.

Disclaimer

The information on this webpage is provided for general informational and educational purposes only and is not intended as investment advice, a recommendation to purchase or sell any security, or an offer or solicitation related to investments. It does not consider your personal financial situation, goals, or risk profile, and all investing carries inherent risks, including the possibility of losing your entire investment. For more details, please review our full disclaimer.

Disclaimers and Limitations